Efficacy of canakinumab in mild or severe COVID‐19 pneumonia

BACKGROUND: Clinicians all around the world are currently experiencing a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Several therapeutic strategies have been used until now but, to date, there is no specific therapy to treat SARS‐CoV‐2 infection. In this study, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Katia, Falasca, Myriam, Di Penta, Ucciferri, Claudio, Auricchio, Antonio, Di Nicola, Marta, Marchioni, Michele, Eleonora, Celletti, Emanuela, Sabatini, Cipollone, Francesco, Vecchiet, Jacopo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8013503/
https://www.ncbi.nlm.nih.gov/pubmed/33465283
http://dx.doi.org/10.1002/iid3.400

Ejemplares similares

Ejemplares similares